Jim Tananbaum and His Contribution to Healthcare Sector
Mindstrong Health recently announced that they had come up with about 14 million US Dollars. This was made possible by several investors who included ARCH Venture and Foresite Capital. This was in a bid to support the organization’s platform of neuropsychiatric treatment and diagnosis. The platform is specially designed to carefully follow around and monitor the different similarities and pattern of interactions on the modern smartphone gadgets. By doing so, they will be able to come up with broad and meaningful parameters of brain function. This platform is aimed at giving and providing a biomarker of cognitive measure and also a biomarker for mood. All this will be made possible by processing certain factors such as speed, attention, memory, and executive function.
Jim Tananbaum, the CEO of Foresite Capital in an earlier statement, said that he acknowledges the role which Mindstrong Health is playing in serving the community. He continues to say that the firm is ensuring that proper health care is provided to the patients who have psychological disorders. Through the coming together of three great and experienced people namely; Paul, Rick, and Tom who have a great technical vision in this field. The efforts are all aimed at providing best healthcare which is state of the art. This is made possible through the tracking of behaviors and different aspects in a patient as it’s done in cases of diabetes and other chronic diseases. Equal treatment is required in the treatment of the mental disorders. Visit Medium for more details.
Jim Tananbaum is the Chief Executive Officer of Foresite Capital Management. Jim has been a leader in investments for over 21 successful Companies including Amira Pharmaceuticals which was later acquired by a different investment franchise known as Bristol-Myers Squipp. Others include Amerigroup and also Jazz Pharmaceuticals. Jim Tanabaum had previously founded and also held the managerial position at GelTex Pharmaceuticals, a company which was later acquired by Genzyme for a price of about one and half billion dollars. Jim Tananbaum has a great academic background. He holds an M.D from the Harvard Medical School and a B.S.E.E from the reputable Yale University.
Jim Tananbaum has been a leading investor in the pharmaceutical and healthcare sectors. Currently, Foresite Capital has under his management recorded over 650 Million US dollars in assets. This makes Jim one of the greatest investors.
Visit officialjimtananbaum.com
Reference: https://www.linkedin.com/in/jim-tananbaum-a7562a7/